These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9156252)

  • 21. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease.
    Pusic I; Pavletic SZ; Kessinger A; Tarantolo SR; Bishop MR
    Bone Marrow Transplant; 2002 Apr; 29(8):709-10. PubMed ID: 12180118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polychemotherapy combined with G-CSF-mobilized donor buffy coat transfusion for granulocytic sarcoma after allogeneic BMT for AML.
    Nachbaur D; Duba HC; Feichtinger H; Kropshofer G; Nussbaumer W; Schwaighofer H; Niederwieser D
    Bone Marrow Transplant; 1997 May; 19(9):947-9. PubMed ID: 9156272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor leukocyte infusion after allogeneic bone marrow transplantation was not effective for relapsed rhabdomyosarcoma.
    Moritake H; Ikuno Y; Tasaka H; Koga H; Miyazaki S; Okamura J
    Bone Marrow Transplant; 1998 Apr; 21(7):725-6. PubMed ID: 9578314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogenic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay.
    Ogawa H; Tsuboi A; Oji Y; Tamaki H; Soma T; Inoue K; Sugiyama H
    Bone Marrow Transplant; 1998 Mar; 21(5):525-7. PubMed ID: 9535047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Donor leukocyte transfusion in a patient with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation: analysis of natural killer cell activity and T-cell receptor repertoire in bone marrow T cells that exhibited graft-versus-leukemia activity].
    Suehiro Y; Muta K; Umemura T; Motomura S; Nishimura J; Nawata H; Kimura N
    Rinsho Ketsueki; 1999 Jan; 40(1):40-5. PubMed ID: 10067095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolated testicular and bone relapse in children with acute myeloblastic leukemia and chronic graft versus host disease after allogeneic BMT.
    Yildirim I; Uçkan D; Cetin M; Tuncer M; Tezcan I
    Turk J Pediatr; 2007; 49(2):206-9. PubMed ID: 17907524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
    Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
    Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary human keratinocytes as targets in predicting acute graft-versus-host disease following HLA-identical bone marrow transplantation.
    van Dijk AM; Kessler FL; Verdonck LF; Stadhouders-Keet SA; van Lier RA; de Gast GC; Otten HG
    Br J Haematol; 2000 Dec; 111(3):791-6. PubMed ID: 11122139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion.
    Porter D; Levine JE
    Semin Hematol; 2006 Jan; 43(1):53-61. PubMed ID: 16412789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
    Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
    Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
    Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe acute graft-versus-host disease after T-cell depleted allogeneic stem cell graft from a second donor caused by persisting T-cells from the first donor.
    Wiesmann A; Bader P; Bamberg M; Faul C; Kanz L; Einsele H
    Bone Marrow Transplant; 2003 Sep; 32(5):511-3. PubMed ID: 12942098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.